Horizon’s Procysbi (Cysteamine Bitartrate) Receives the US FDA’s Approval for Delayed Release Oral Tablets

 Horizon’s Procysbi (Cysteamine Bitartrate) Receives the US FDA’s Approval for Delayed Release Oral Tablets

Horizon Therapeutics’ Tepezza (teprotumumab-trbw) Receives the US FDA’s Approval as the First Therapy for Thyroid Eye Disease

Shots:

  • The US FDA has approved Procysbi for adults and children one year of age and older living with nephropathic cystinosis
  • Procysbi (cysteamine bitartrate) is a delayed-release capsules and delayed-release oral granules also a cystine-depleting agent indicated to treat nephropathic cystinosis in adults and pediatric patients 1 year of age and older
  • Procysbi will continue to be available in 25 mg and 75 mg strengths while the 75mg and 300mg is expected to be available in H1’20

Click here to­ read full press release/ article | Ref:  Horizon Therapeutics | Image: Horizon Therapeutics

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post